M. de Cesare

发表

Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.

G. Giannini, F. Zunino, L. Musso, 2014, European journal of medicinal chemistry.

Improved Apoptotic Cell Death in Drug-Resistant Non–Small-Cell Lung Cancer Cells by Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Based Treatment

N. Zaffaroni, F. Zunino, P. Perego, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Supersulfated low-molecular weight heparin synergizes with IGF1R/IR inhibitor to suppress synovial sarcoma growth and metastases.

N. Zaffaroni, E. Favini, C. Lanzi, 2018, Cancer letters.

Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models.

F. Zunino, R. Supino, P. Perego, 2003, Biochemical pharmacology.

Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo.

M. Daidone, N. Zaffaroni, F. Zunino, 2004, Carcinogenesis.

Isoxazolo(aza)naphthoquinones: a new class of cytotoxic Hsp90 inhibitors.

G. Giannini, F. Zunino, L. Musso, 2012, European journal of medicinal chemistry.

A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.

L. Tartaglia, F. Zunino, M. Palumbo, 2001, Cancer research.

Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity.

A. Ferrari, F. Zunino, P. Perego, 2001, Journal of medicinal chemistry.

FoxO‐1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models

N. Zaffaroni, P. Perego, N. Carenini, 2018, Biochemical pharmacology.

CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts

N. Zaffaroni, M. Pennati, C. De Marco, 2016, Journal of Translational Medicine.

Synthesis and biological evaluation of imidazolo[2,1-b]benzothiazole derivatives, as potential p53 inhibitors.

F. Zunino, M. Christodoulou, D. Passarella, 2011, Bioorganic & medicinal chemistry.

High efficacy of CpG-ODN, Cetuximab and Cisplatin combination for very advanced ovarian xenograft tumors

N. Zaffaroni, M. de Cesare, E. Tagliabue, 2013, Journal of Translational Medicine.

Down-regulation of human telomerase reverse transcriptase through specific activation of RNAi pathway quickly results in cancer cell growth impairment.

M. Daidone, N. Zaffaroni, F. Zunino, 2007, Biochemical pharmacology.

Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.

F. Zunino, P. Perego, N. Carenini, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Efficacy and toxicity profile of oral topotecan in a panel of human tumour xenografts.

F. Zunino, C. Pisano, M. de Cesare, 2000, European journal of cancer.

Stimulation of the apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumour xenografts.

F. Zunino, D. Polizzi, A. Giusti, 1998, British Journal of Cancer.

Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenografts.

F. Zunino, R. Supino, D. Polizzi, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.

G. Giannini, F. Zunino, L. Musso, 2016, European journal of medicinal chemistry.

Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts.

G. Zupi, F. Zunino, P. Perego, 2005, European journal of cancer.

Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrin αVβ3.

L. Belvisi, N. Zaffaroni, P. Perego, 2012, Journal of medicinal chemistry.

Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo.

F. Zunino, G. Capranico, R. Supino, 1997, Journal of the National Cancer Institute.

Sulfonates-PMMA nanoparticles conjugates: a versatile system for multimodal application.

G. Sotgiu, F. Zunino, K. Sparnacci, 2012, Bioorganic & medicinal chemistry.

Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft

F. Zunino, P. Perego, N. Carenini, 2008, Cancer biology & therapy.

Novel 1H-pyrrolo[2,3-b]pyridine derivative nortopsentin analogues: synthesis and antitumor activity in peritoneal mesothelioma experimental models.

N. Zaffaroni, M. Pennati, P. Diana, 2013, Journal of medicinal chemistry.

Targeting Peptidyl-Prolyl Isomerase Pin1 to Inhibit Tumor Cell Aggressiveness

P. Perego, N. Carenini, Luisa Albano, 2016, Tumori.

Synergistic Antitumor Effects of Novel HDAC Inhibitors and Paclitaxel In Vitro and In Vivo

N. Zaffaroni, F. Zunino, C. Pisano, 2011, PloS one.

Design, synthesis, and biological evaluation of novel cRGD-paclitaxel conjugates for integrin-assisted drug delivery.

F. Vasile, L. Belvisi, F. Zunino, 2012, Bioconjugate chemistry.

Isoxazolo(aza)naphthoquinones: a new class of cytotoxic Hsp90 inhibitors.

G. Giannini, F. Zunino, L. Musso, 2012, European journal of medicinal chemistry.

The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.

N. Zaffaroni, F. Zunino, C. Lanzi, 2012, Biochemical pharmacology.

Modulation of cell growth and cisplatin sensitivity by membrane gamma-glutamyltransferase in melanoma cells.

P. Apostoli, F. Zunino, P. Perego, 2006, European journal of cancer.

Tissue distribution, antitumour activity and in vivo apoptosis induction by MEN10755 in nude mice.

F. Zunino, C. Maggi, D. Polizzi, 2001, European journal of cancer.

Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines.

F. Zunino, R. Supino, D. Polizzi, 2001, Current medicinal chemistry.

2-Acryloyl-4,5-methylenedioxyphenol: A Small Molecule Endowed with Antidermatophytic Activity

L. Musso, S. Dallavalle, R. Cincinelli, 2019, Letters in Drug Design & Discovery.

Methylprednisolone and chlorpromazine alone or in combination for the control of cisplatin-induced emesis.

N. Panza, G. Pacilio, M. de Cesare, 1984, Cancer treatment reports.

Effects of MnDPDP and ICRF-187 on Doxorubicin-Induced Cardiotoxicity and Anticancer Activity.

M. de Cesare, R. Towart, J. Karlsson, 2012, Translational oncology.

YM155 sensitizes triple‐negative breast cancer to membrane‐bound TRAIL through p38 MAPK‐ and CHOP‐mediated DR5 upregulation

M. Daidone, N. Zaffaroni, M. Pennati, 2015, International journal of cancer.

Biodistribution of haematoporphyrin analogues in a lung carcinoma model.

R. Marchesini, M. Tronconi, F. Zunino, 1995, Cancer letters.

A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides.

A. Tesei, C. Leonetti, M. Porru, 2014, Journal of medicinal chemistry.

8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.

F. Zunino, R. Supino, E. Borowski, 1999, Journal of medicinal chemistry.

E-ring-modified 7-oxyiminomethyl camptothecins: Synthesis and preliminary in vitro and in vivo biological evaluation.

G. Giannini, F. Zunino, C. Pisano, 2008, Bioorganic & medicinal chemistry letters.

Biological properties of IDN5174, a new synthetic camptothecin with the open lactone ring.

M. Zucchetti, F. Zunino, P. Perego, 2006, Cancer research.

Configurational requirements of the sugar moiety for the pharmacological activity of anthracycline disaccharides.

F. Zunino, G. Capranico, R. Supino, 1999, Biochemical pharmacology.

Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models.

A. Tesei, P. Ulivi, F. Zunino, 2005, Neoplasia.

Efficacy of the Novel Camptothecin Gimatecan against Orthotopic and Metastatic Human Tumor Xenograft Models

F. Zunino, M. de Cesare, S. Veneroni, 2004, Clinical Cancer Research.

Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin.

F. Zunino, P. Perego, N. Carenini, 2001, Cancer research.

Novel 7-substituted camptothecins with potent antitumor activity.

A. Ferrari, F. Zunino, P. Perego, 2000, Journal of medicinal chemistry.

3‐Arylidene‐N‐hydroxyoxindoles: A New Class of Compounds Endowed with Antitumor Activity

A. L. Fallacara, M. Botta, F. Zunino, 2016, ChemMedChem.

Synthesis and cytotoxic activity of polyamine analogues of camptothecin.

G. Giannini, F. Zunino, L. Musso, 2006, Journal of medicinal chemistry.

miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells.

N. Zaffaroni, M. Pennati, R. Valdagni, 2014, Biochemical pharmacology.

Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin

N. Zaffaroni, M. Pennati, M. de Cesare, 2015, Oncotarget.

PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins

N. Zaffaroni, C. Lanzi, G. Cassinelli, 2015, Oncotarget.

Antitumor activity of a novel homodimeric SMAC mimetic in ovarian carcinoma.

F. Vasile, D. Potenza, L. Belvisi, 2014, Molecular pharmaceutics.

Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity

M. Colombo, P. Seneci, D. Delia, 2013, Cell Death and Disease.

Efficacy of a Selective Binder of αVβ3 Integrin Linked to the Tyrosine Kinase Inhibitor Sunitinib in Ovarian Carcinoma Preclinical Models

P. Perego, E. Scanziani, M. de Cesare, 2019, Cancers.

Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism

N. Zaffaroni, M. Pennati, V. Zuco, 2017, Journal of Hematology & Oncology.

miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma

M. Dugo, N. Zaffaroni, G. Colella, 2022, Cancer Gene Therapy.

Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968

Gabriella Morini, Sergio Penco, Claudio Pisano, 2008, Molecular Cancer Therapeutics.

1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment.

A. Tesei, N. Zaffaroni, J. Trepel, 2017, Journal of medicinal chemistry.

Glycosaminoglycan-enriched extracellular matrix surrounds intraductal carcinoma of human breast: histochemical study.

F. D'armiento, M. de Cesare, R. Vecchione, 1985, Applied pathology.

Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition.

S. Canevari, N. Zaffaroni, F. Zunino, 2012, Biochemical pharmacology.

Antitumor activity of the combination of synthetic retinoid ST1926 and cisplatin in ovarian carcinoma models.

F. Zunino, R. Supino, C. Pisano, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Eradication of Ovarian Tumor Xenografts by Locoregional Administration of Targeted Immunotherapy

S. Ménard, F. Zunino, M. de Cesare, 2008, Clinical Cancer Research.

TLR9 agonists oppositely modulate DNA repair genes in tumor versus immune cells and enhance chemotherapy effects.

S. Ménard, L. De Cecco, D. Delia, 2011, Cancer research.

Synergistic Antitumor Activity of Cetuximab and Namitecan in Human Squamous Cell Carcinoma Models Relies on Cooperative Inhibition of EGFR Expression and Depends on High EGFR Gene Copy Number

N. Zaffaroni, F. Zunino, S. Veronese, 2013, Clinical Cancer Research.

Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.

F. Zunino, S. Dallavalle, G. Morini, 2009, European journal of medicinal chemistry.

Design, modeling, synthesis and biological activity evaluation of camptothecin-linked platinum anticancer agents.

N. Zaffaroni, F. Zunino, D. Colangelo, 2013, European journal of medicinal chemistry.

Novel cytotoxic 7-iminomethyl and 7-aminomethyl derivatives of camptothecin.

A. Ferrari, F. Zunino, P. Perego, 2001, Bioorganic & medicinal chemistry letters.

Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat

C. Tripodo, N. Zaffaroni, F. Zunino, 2018, Hematological oncology.

High Efficacy of Intravenous Gimatecan on Human Tumor Xenografts

M. de Cesare, 2018, AntiCancer Research.

Remarkable antitumor activity of 5'-deoxy-5-fluorouridine in human colorectal tumor xenografts.

F. D. De Braud, F. Zunino, M. de Cesare, 1994, Anticancer research.

Sensitization of ovarian carcinoma cells to the atypical retinoid ST1926 by the histone deacetylase inhibitor, RC307: enhanced DNA damage response

F. Zunino, V. Benedetti, V. Zuco, 2009, International journal of cancer.

Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series.

F. Zunino, S. Dallavalle, V. Benedetti, 2007, Biochemical pharmacology.

Intracellular accumulation and DNA damage persistence as determinants of human squamous cell carcinoma hypersensitivity to the novel camptothecin ST1968.

F. Zunino, V. Benedetti, F. Bucci, 2008, European journal of cancer.

Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts.

F. Zunino, R. Supino, C. Lanzi, 2003, Molecular cancer research : MCR.

Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.

N. Zaffaroni, F. Zunino, P. Perego, 2012, Journal of inorganic biochemistry.

Ascites Regression and Survival Increase in Mice Bearing Advanced-stage Human Ovarian Carcinomas and Repeatedly Treated Intraperitoneally With CpG-ODN

M. Campiglio, F. Zunino, R. Supino, 2010, Journal of immunotherapy.

Lonidamine alone and in combination with other chemotherapeutic agents in the treatment of cancer patients.

G. Pacilio, M. de Cesare, G. Cartenì, 1984, Oncology.

Dimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part II: Structural and biological characterization.

M. Bolognesi, M. Civera, F. Vasile, 2012, Bioorganic & medicinal chemistry.

Design, synthesis and biological evaluation of novel dimeric and tetrameric cRGD-paclitaxel conjugates for integrin-assisted drug delivery.

N. Zaffaroni, P. Perego, N. Carenini, 2015, Organic & biomolecular chemistry.

Synthesis and Superpotent Anticancer Activity of Tubulysins Carrying Non-hydrolysable N-Substituents on Tubuvaline.

N. Zaffaroni, M. Zanda, P. Lazzari, 2017, Chemistry.

Synthesis and Evaluation of the Tumor Cell Growth Inhibitory Potential of New Putative HSP90 Inhibitors

M. Vasconcelos, L. Musso, S. Dallavalle, 2018, Molecules.

Caffeic acid phenethyl ester targets ubiquitin-specific protease 8 and synergizes with cisplatin in endometrioid ovarian carcinoma cells.

P. Perego, N. Carenini, S. Linder, 2022, Biochemical pharmacology.